Gabapentin
Product Images NDC 68071-2308

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 68071-2308). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2308 9)

Gabapentin is a medication used to treat seizure disorders and nerve pain. The text is a label of Gabapentin 300mg, with specific details such as Lot number, manufacturer, and expiration date. It also warns to keep the medicine out of reach of children and includes information to call a doctor if side effects occur. The medication should be stored at a controlled temperature of 59-86°F.*

FDA Label Image

Figure 1 (Image 01)

This appears to be a table or graph displaying pain scores and treatment options for a certain period of time. It shows different dosages of medication, including Gabapentin at 3600 mg per day, and a placebo option. The table/graph includes a baseline measurement and measures taken over the course of weeks. The main heading seems to be "Mean Pain Score".*

FDA Label Image

Figure 2 (Image 02)

This is a chart that shows the results of a study on pain relief medication. It illustrates the mean pain score of a group of patients over a 7-week period, including a 4-week fixed dose period. The study includes a placebo and two doses of Gabapentin - 1800mg/day and 2400mg/day. The X-axis shows the weeks of the study and the Y-axis shows the mean pain score. There is no further information to provide.*

FDA Label Image

Figure 3 (Image 03)

FDA Label Image

Cockcroft And Gault Equation (Image 04)

FDA Label Image

Gabapentin Structural Formula (Image 05)

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Image 09)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.